| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | XAIR | Common Stock | Sale | $425,979 | -65,500 | -14% | $6.50 | 408,027 | 30 Jun 2022 | Direct | F1, F2 |
| transaction | XAIR | Common Stock | Sale | $17,094 | -2,600 | -16% | $6.57 | 13,733 | 30 Jun 2022 | Held by Dandelion Investments Ltd. | F1, F3 |
| Id | Content |
|---|---|
| F1 | The sale was made to satisfy an Israeli tax obligation resulting from the reporting person's ownership of shares of Advanced Inhalation Therapies (AIT) Ltd., an Israeli corporation, which merged with Beyond Air, Inc. (formerly known as AIT Therapeutics, Inc.), a Delaware corporation, on January 13, 2017. |
| F2 | The sale price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.47 to $6.59, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. |
| F3 | The sale price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.57 to $6.585, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. |